Eli Lilly Close To Settlement Over Marketing Of Zyprexa


The AP (1/15) reports, "Drugmaker Eli Lilly and Co. is close to agreeing to a $1.4 billion settlement related to a government investigation into the marketing of its top seller Zyprexa, according to a New York Times report." There were documents discovered that "show Lilly downplayed the drug's risks and marketed it for unapproved uses" and "lawsuits have made similar claims, accusing Lilly of pushing doctors to prescribe Zyprexa for 'off-label' conditions like Alzheimer's disease."

The New York Times (1/15, Harris) reports, "The amount of the settlement is a record sum for so-called corporate whistle-blower cases," and "among the charges, Lilly has been accused of a scheme stretching for years to persuade doctors to prescribe Zyprexa to two categories of patients — children and the elderly — for whom the drug was not federally approved and in whom its use was especially risky."

From the American Association for Justice news release.

1 Comment For This Post

  1. DannyHaszard
    January 17th, 2009 | 1:26 pm

    Eli Lilly: Indy-based pharmaceutical company pleads guilty to promoting Zyprexa for unapproved uses; is slapped with $1.4 billion criminal fine, the largest ever placed on a U.S. company.
    Zyprexa Claims being Stonewalled.
    Where is the money going as many victim claimants haven’t been paid yet?
    Something fishy going on here?
    Conflict of interest.
    Eli Lilly promotes sales of their #1 drug (Zyprexa $4.8 billion year) that can *cause* diabetes and then turn around and make billions selling more drugs to treat the diabetes.
    Eli Lilly’s # 1 cash cow Zyprexa has been overprescribed and linked to a ten times greater risk of causing type #2 diabetes and increased risk of heart attacks.
    Daniel Haszard Zyprexa patient who got the diabetes from it.
    http://www.zyprexa-victims.com

Leave a Reply

Trackback URL

http://www.pissd.com/2009/01/eli-lilly-close-to-settlement-over-marketing-of-zyprexa/trackback/